NOC — Claude Opus 4.8

I'll research NOC before writing the preview. Let me start by gathering recent transcripts, releases, filings, and news.Let me read the most recent earnings materials (2026Q1) and get recent news.Good, I have the Q1 2026 release. Now let me get the Q1 transcript, the prior-year Q2 comp, recent news, and stock price.Let me get the prior-year Q2 2025 release for comparison and check recent defense sector news.I have strong material. Let me do one more targeted search for recent NOC-specific news/catalysts (F/A-XX, awards) in the weeks before the print.# Northrop Grumman (NOC) — Q2 2026 Earnings Preview

Reports Tuesday, July 21, 2026, before the open | Conference call 9:30 a.m. ET

1. The setup in one paragraph

Northrop reports into a paradoxical backdrop: demand has arguably never been stronger — record-ish backlog, a $1.5 trillion FY27 defense budget request, accelerating B-21 and Sentinel — yet the stock has been one of the weakest large-cap defense names of 2026. Shares closed at $524 on July 20, down roughly 11% year-to-date and about 32% off the early-March high near $768. The Q1 print in April was a turning point: despite a clean beat, the stock fell ~7% the day of the report and kept sliding, as investors fixated on the ~$2.5B of company-funded B-21 capital investment, cash-flow timing, and a rising-rate/"cheap-drone" narrative. This quarter is less about the Q2 numbers themselves and more about (a) whether management finally raises guidance the way it did at this point in 2025, and (b) the read-through to two enormous binary catalysts sitting in Q3 — the F/A-XX Navy fighter down-select and continued B-21 rate-ramp economics.

2. What the Street expects

Metric	Q2 2026 Consensus	Q2 2025 Actual	Y/Y
Revenue	~$10.8B	$10.35B	+4.4%
EPS	~$6.83	$8.15 (GAAP)	−16.2%

Read the EPS "decline" carefully. The 16% drop is optically ugly but largely a comp artifact. Q2 2025 included a $1.04/share after-tax gain from the training-services divestiture plus a $76M favorable Sentinel EAC adjustment. Stripping the divestiture gain, prior-year "clean" EPS was ~$7.11, so the true underlying decline the Street models is smaller — driven by lower FAS/CAS pension income, higher interest expense, and a tougher Mission Systems margin comp (Q2'25 MS margin was an elevated 14.0% on restricted-award timing).

Sequential context matters more here. On the Q1 call, CFO John Greene guided to "high single-digit sequential sales growth" in Q2 off the Q1 base of $9.88B — i.e., ~$10.6–10.7B. Consensus of ~$10.8B implies the Street is modeling toward the high end / slight beat. Northrop has a long history of back-half-weighted revenue and cash, so a modest Q2 with reaffirmed full-year targets would be entirely in character.

3. The single biggest question: does guidance get raised?

Current FY2026 guidance (reaffirmed, not raised, at Q1): - Sales: $43.5B – $44.0B - Segment operating income: $4,850M – $5,000M (low-to-mid 11% margin) - MTM-adjusted EPS: $27.40 – $27.90 - Free cash flow: $3.1B – $3.5B - CapEx: raised to ~$1.85B (from prior plan, +$200M for B-21 capacity)

Why this is the crux: In 2025, Northrop raised segment OI, EPS and FCF guidance at the Q2 print. This year it only reaffirmed at Q1. With Q1 organic sales +5%, segment margin 10.8%, and management repeatedly citing an "opportunity-rich" environment, the bull case wants a raise (especially on segment OI/EPS). A simple reaffirmation — particularly on free cash flow, given the stepped-up capex — could disappoint a market already skeptical of the cash story. Watch the full-year margin cadence commentary; management has said margins should improve through the year on "performance, production timing and mix."

Quick sanity check on EPS math: Q1 came in at $6.14. The full-year MTM-adj midpoint (~$27.65) implies ~$21.5 across the remaining three quarters, or ~$7.1–7.3/quarter — so the ~$6.83 Q2 consensus is consistent with the usual H2 skew, not a signal of deterioration.

4. Program-level watch list

B-21 Raider (Aeronautics — nearing 10% of revenue). The defining swing factor. In Q1, Northrop finalized a deal with the Air Force to increase the annual production rate ~25%, funded partly by reconciliation dollars plus ~$2.5B of company-funded capex (mostly '27–'29), and received the Lot 4 LRIP award. Key things to probe: any change to the LRIP EAC (management said "no significant change" in Q1, with higher early-lot costs offset by better later-lot profitability), the pace of the ~$200M of 2026 B-21 capex, and any movement toward a larger program of record. Management asserted the deal pushes program ROIC above cost of capital — the market will want that reinforced. Aerial-refueling testing began in early Q2; first aircraft to Ellsworth AFB is targeted for 2027.

Sentinel (Defense Systems — ~6–7% of revenue, ~1/3 of DS). Growing double digits and ramping on a re-baselined program. Look for confirmation of the Milestone B decision later in 2026, first flight in 2027, and IOC in the early 2030s. Silo prototype construction began in Q1.

F/A-XX (the Q3 catalyst). Management expects a Navy down-select in Q3 (August) between Northrop and Boeing, and explicitly said a win would be upside to current sales/EPS guidance. This overhangs the whole print — expect pointed questions given the CNO's public comment that one bidder "lacks the capacity" to deliver on time. Any color on funding certainty and positioning will move sentiment.

Space Systems — the margin risk to watch. Q1 was the soft spot: sales −3% (NGI wind-down) and a $71M unfavorable EAC on the GEM 63XL solid rocket motor tied to a launch anomaly. Management said it saw no other significant negative EACs, but a second quarter of space charges would feed the bear thesis. Offsets: strong book-to-bill (~1.3 in 2025), SDA Tranche 3 tracking-layer ramp, and restricted growth.

Munitions / Solid Rocket Motors & Missile Defense (each ~10% of company sales). Framed as the fastest-growing part of the portfolio. Northrop is scaling as a second-source SRM supplier (GMLRS, PrSM, Hellfire, AIM-9X; qualifying for PAC-3), with tactical SRM capacity already doubled and more coming by 2027. Missile-defense catalysts: Golden Dome C2 role and the Glide Phase Interceptor (now $1.3B total). Note the competitive backdrop — Lockheed just unveiled a cheaper PAC-3 "ACE" interceptor (July 20), underscoring customer appetite for lower-cost, faster-to-field solutions.

5. Backlog, bookings and cash

Backlog was ~$95.6B at Q1 (roughly flat vs. year-end), with a Q1 book-to-bill of ~1.0 ($9.8B awards). Watch for a step-up as FY26 appropriations and reconciliation funds flow onto contracts — management flagged large awards still to be booked.
Cash flow is seasonal and back-half loaded. H1 is typically a cash use (Q1 2026 FCF was −$1.8B, in line with prior year). Don't be alarmed by a soft H1 cash number; the real test is whether the full-year $3.1–3.5B FCF range holds despite higher capex. Management said it is "working to offset" the incremental B-21 investment.
Capital returns: Q1 buybacks slowed sharply (~$68M vs. $480M a year earlier) as cash went to debt paydown ($527M) and reinvestment. With the shares down hard, watch whether repurchase pace picks back up — a lever the bulls will want pulled.

6. Macro & policy cross-currents

Budget tailwind: A $1.5T FY27 request (+44%), with the base budget alone up ~30%, sustaining B-21, Sentinel, IBCS, E-2D and restricted work — a multi-year demand signal management leans on heavily. Global defense spending is up ~40% over the past decade and rising.
New supply-chain executive order (July 20): The administration ordered contractors to map supply chains and cut ties with "foreign suppliers of concern" (notably China), with waivers requiring proof that alternatives are exhausted. A potential compliance/cost overhang across the sector worth a question.
Rate/valuation risk: The macro tape now features a hawkish Fed under new Chair Kevin Warsh, with policymakers openly discussing hikes. Higher-for-longer rates pressure both NOC's ~$14.4B debt/interest expense and the multiple on a long-duration, capex-heavy defense compounder that had re-rated sharply — a plausible piece of why the stock de-rated from its March highs.
The "cheap-drone" debate: The bear narrative — that warfare is shifting toward low-cost attritable systems and new entrants (Anduril, SpaceX-type players) — was explicitly cited in the pre-earnings press setup. Expect management to counter with its munitions/counter-UAS positioning and capacity investments.

7. Bull vs. bear into the print

Bull case: Reaffirmed-to-raised guidance; B-21 rate ramp with improving lifetime economics and ROIC above cost of capital; Sentinel and munitions compounding; a potential F/A-XX win as free option value; record backlog with reconciliation dollars still to convert; a stock that has already de-rated ~30% from highs, resetting expectations.

Bear case: Another Space EAC/charge; only a reaffirmation (especially on FCF) as capex climbs; tough Q2 comp masking limited underlying EPS growth; rising-rate pressure on the multiple and interest costs; structural questions about attritable/low-cost competition; and a still-back-half-loaded cash story that requires a big Q4.

8. What likely moves the stock on the day

Guidance action — a raise (segment OI/EPS/FCF) vs. reaffirmation is the primary driver.
Free cash flow reassurance — any hint the $3.1–3.5B range is at risk from B-21 capex would hurt.
Space Systems margins — clean quarter vs. a second charge.
F/A-XX commentary — timing/confidence ahead of the August decision.
Bookings/book-to-bill — evidence reconciliation and FY26 funds are converting to backlog.

Bottom line: Consensus (~$10.8B revenue, ~$6.83 EPS) sets a beatable bar given the sequential guide and back-half skew, so the operative debate is guidance and cash — not the headline Q2 print. After a sharp de-rating, the risk/reward increasingly hinges on management converting an undeniably strong demand environment into raised targets and a credible free-cash-flow bridge, with the F/A-XX decision looming as the next major catalyst just weeks after this report.

Sources: NOC Q1 2026 earnings release and conference call transcript (April 21, 2026); Q2 2025 earnings release (July 22, 2025); daily news digests and NOC price history through July 20, 2026. This is an informational earnings preview, not investment advice.